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ABBREVIATIONS 
ABW    – Actual Body Weight 
ACE     –  Angiotensin Converting Enzyme 
ADRs    – Adverse Drug Reactions 
APD     –  Acute Pulmonary Disease 
ARB     –  Angiotensin Receptor Blocker 
BD    –  Twice Daily  
BNF     –  British National Formulary 
CAPD    – Continuous Ambulatory Peritoneal Dialysis 
CCF     – Congestive Cardiac Failure 
CG     – Cockcroft-Gault 
CHF     – Congestive Heart Failure 
CKD     – Chronic Kidney Disease 
ClCr     –  Creatinine Clearance 
CRF     – Chronic Renal Failure 
CVA     –  Cerebrovascular Accident 
CVD     – Cardio Vascular Disease 
DCI     –  Dialysis Clinic, Inc 
DM    – Maintenance Dose  
DRPs     –  Drug Related Problems 
eGFR     –  Estimated Glomerular Filtration Rate  
ESRD    – End Stage Renal Disease    
GFR    –  Glomerular Filtration Rate 
HD     –  Heamodialysis 
IBW    – Ideal Body Weight 
IHD     –  Ischaemic Heart Disease 
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IV     – Intravenous     
KDOQI    –  Kidney Disease Outcomes Quality Initiative 
KF    – Kidney Function 
LBW    – Lean Body Weight 
LRTI     – Lower Respiratory tract Infection   
MDRD    – Modification of Diet in Renal Disease 
NAPQI   – N-acetyl-P-benzoquinoneimine 
NFK     –  National Kidney Foundation 
NSAIDs    –  Non Steroidal Anti-inflammatory Drugs  
NTI    –  Narrow Therapeutic Index  
OD    – Once Daily 
PDR     –  Physician Desk Reference 
PO     – Per Oral 
RI     –  Renal Impairment 
RF     – Renal Failure  
RRT     –  Renal Replacement Therapy 
SD     – Standard Deviation 
TDM     –  Therapeutic Drug Monitoring 
TID    – Thrice Daily 
τ    – Dosing Interval 
q.8.h     – Every Eight Hours 
q.6.h    – Every Six Hours 
q.12.h    –  Every Twelve Hours 
UTI     –  Urinary Tract Infection  
WHO     – World Health Organisation 
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ABSTRACT 
 
BACKGROUND 
Chronic kidney disease is a common and progressive illness that may be harmful 
and may have deleterious effects. Inappropriate dosing in patients with renal 
dysfunction can cause toxicity or ineffective therapy. Dose adjustment in patients 
with renal failure reduces both the cost of the drug therapy and the risk of ADRs. 
OBJECTIVE 
 To understand the prescribing pattern of antimicrobials and cardiovascular 
drugs in patients with renal function impairment. 
 
 To understand drug dosage individualization of all renally excreted 
antimicrobials and cardiovascular drugs that necessitates dosage 
adjustment in patients with renal function impairment. 
DESIGN 
Prospective descriptive study 
STUDY DURATION 
9 months (from December 2018 to August 2018) 
SETTING 
A 700 bedded multi-specialty tertiary care teaching hospital 
PATIENTS 
All in patients with estimated serum creatinine value more than 1.7mg/dL 
(Normal range: 0.8 – 1.2 mg/dL), prescribed with at least one antimicrobial drug 
or cardiovascular drug or both were included in the study. 
METHOD 
Clinical and demographic details of the eligible patients were collected in a 
structured proforma after obtaining approval from the Institutional Review Board. 
Creatinine clearance or estimated glomerular filtration rate of the patient were 
calculated using Cockroft-Gault equation and Modified Diet in Renal Disease 
equation respectively with the help of Micromedex calculators.  The dose of all 
drugs with potential nephrotoxicity or renally excreted drugs was evaluated using 
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the published drug dosing guidelines. When necessary the new dosages or dosing 
intervals were optimized to the patient’s individual degree of renal impairment 
using relevant equations. 
RESULTS 
20 patients had moderate renal impairment while 46 had severe and 37 had end 
stage renal dysfunction. 1016 drugs in 103 patients were evaluated in the present 
study with an average of 10 drugs per patient. Of these 1016 studied drugs 98 
(9.64%) required dose adjustment where 244 (24.01%) were adjusted and 83 
(8.16%) were not adjusted. It was found also that most of the drugs requiring dose 
adjustment were antibiotics (41.77%) followed by antihypertensives (13.67%). 
Major category of errors identified were overdose (61.53%) and wrong frequency 
of administration (23.07%). About 15.38% of the drugs were to be avoided strictly. 
It was also found that 13.12% of prescribed drugs had interaction. The most 
common interaction was identified as Pantaprazole vs Torsemide and was found 
in 4.17% of patients. Nephrotoxic drug interactions were observed in 2.79% of 
patients. Around 1.84% of drugs had narrow therapeutic index. These were 
prescribed in 13.5% of patients. Prazosin (2%) theophylline (8%) and Digoxin 
(4%) were the drugs with narrow therapeutic index. 
CONCLUSION 
Recommended dosage guidelines in renally impaired patients were followed in 
82.6% of prescriptions whereas only 17.39% were found to be deviated. Findings 
of the present study revealed that the overall consistency was good when 
compared with similar studies reported. 
Introduction 
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INTRODUCTION 
The most important contribution of the kidney to overall maintenance of 
body homeostasis is the urinary excretion of water, endogenous substances and 
toxins. Through the combined processes of glomerular filtration, tubular secretion, 
and tubular reabsorption, the nephron, as the functional unit of the kidney, 
maintains balance between input and output of water and solutes from the body. 
Thus the kidney is the key organ responsible for maintenance of homeostasis.1 this 
is represented as: 
Renal deficiency can be caused by inadequate blood flow to the kidney, renal 
and systemic diseases and disorders related to the urinary tract obstruction.  The 
major manifestations of altered kidney function are the effects on excretion of 
metabolic wastes and on maintenance of Na +, K + water, and acid-base balance. 
Failure to excrete urea and other metabolic wastes adequately, manifested as 
progressive elevation of blood urea nitrogen (BUN) and serum creatinine.  In the 
absence of adequate renal clearance of excessive amounts of water, Na+, K+, or 
acids may result in water, electrolyte and acids-base abnormalities that can be life-
threatening. Generally speaking, the renal deficiency includes also the endocrine 
and metabolic dysfunction. 
The two principle organs are responsible for the elimination of drugs and their 
metabolites from the body are the liver and kidney.2 Kidney does the major work 
of the urinary system. Functions of the kidney include the following 
 
 Regulation of blood ionic composition 
 Regulation of blood pH 
 Regulation of blood volume 
 Regulation of blood pressure  
 Maintenance  of blood osmolarity 
Rate of excretion = rate of filtration + rate of secretion - rate of reabsorption 
 
Introduction 
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 Production of hormones 
 Regulation of blood glucose level 
 Excretion waste and foreign substances.3 
Kidney disease is defined as the presence of kidney damage or a reduction in 
GFR for a period of three months or longer. Kidney disease is increasingly 
recognised as a significant health issue in the population.4 In particular, older 
patients are at a higher risk of developing advanced disease and related decline in 
renal function and the use of multiple medications to treat comorbid conditions. 
Chronic kidney disease can affect glomerular blood flow and filtration, tubular 
secretion and reabsorption and renal bio activation and metabolism. Drug 
absorption, bioavailability, protein binding, distribution volume, and non-renal 
clearance (metabolism) also can be altered in these patients.5 
Renal failure is used primarily to denote failure excretory function of kidneys, 
leading to retention of nitrogenous waste products of metabolism. Various other 
aspects of renal function may fail at the same time, including the regulation of 
fluid and electrolyte status and the endocrine function of the kidney. Renal failure 
can be divided according to clinical presentation into acute renal failure 
(ARF) and chronic renal failure (CRF).6 The severe condition (end-stage) of both 
is named as uremia. ARF is a heterogeneous group of disorders, which is 
characterized by a sudden (within hours to days) deterioration of renal function 
and usually associated with oliguria   (< 400ml per day in (adult) or anuria (< 
100ml per day in adult) resulting in accumulation in the blood of nitrogenous 
wastes that would normally be excreted in the urine. The patient presents with a 
rapidly rising blood urea nitrogen and serum creatinine.  Other compounds 
including uric acid, phosphate, and sulphates are also accumulated.  Glomerular 
filtration rate (GFR) decrease plays a central role in pathogenesis of ARF.  Most 
of the patients with ARF present oliguria, which is named as oliguric type of ARF. 
The ARF without oliguria is named as non-oliguric type of ARF.  Acute renal 
failure may be observed in patients with previously normal renal function or 
patients whose prior renal function was impaired but stable. Urine volume may be 
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normal at any time in mild forms of acute renal failure, the diminished urine 
volume is commonly but not always seen. Some patients may be anuric, some 
may be oliguric. 
The incidences of prevalence of kidney failure are rising and the outcomes are 
poor. The kidney provides the final common pathway for execration of most drugs 
and their metabolites. Inappropriate dosing in patients with chronic kidney disease 
can cause toxicity or ineffective therapy. The major outcomes of CKD regardless 
to cause include progression to kidney failure, complications of decreased kidney 
function and CVD. Increasing evidence indicates that some of these adverse 
outcomes can be prevented or delayed by early detection and treatment. 
Unfortunately, CKD is under diagnosed and under treated, resulting in lost 
opportunities for prevention, in part because of lack of agreement on a definition 
and classification of stages in the progression of chronic kidney disease and a lack 
of uniform application of simple tests for detection and evaluation. 
Renal dysfunction can affect the pharmacokinetic and pharmacodynamics 
action of drug. Dosage adjustment in renal failure is critical because drug or its 
active metabolites can accumulate and additional morbidity and cost. In many 
drugs like aminoglycosides antibiotics, H2 receptor antagonists, ACE inhibitors, 
Digoxin, Lithium are eliminated primarily unchanged through the kidney. Dosage 
adjustment in renal failure can easily be achieved by estimating the creatinine 
clearance based on serum creatinine, age, weight, gender; calculating the 
individual elimination capacity for a given drug; and adjusting dose and/or dosing 
interval. Dosage adjustment in patients with renal failure reduces the risk of 
adverse drug reactions 
Risk factors for the chronic kidney disease and its outcomes7 
S.No Risk factors Definition Examples 
1. 
Susceptibility 
factors 
Increase susceptibility to 
kidney damage 
Older age, family history of 
CKD, reduction in kidney 
mass, low birth weight, low 
Introduction 
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income or education 
2. 
Initiation 
factors 
Directly initiate kidney 
damage 
Diabetes, high blood 
pressure, autoimmune 
disease, systemic infections, 
urinary stones, lower 
urinary tract obstruction, 
drug toxicity 
3. 
Progressive 
factors 
Cause worsening kidney 
damage and faster 
decline in kidney 
function after initiation 
of kidney damage 
Higher level of proteinuria, 
higher blood pressure, poor 
glycemic control in 
diabetes, smoking 
4. 
End – stage 
factor 
Increase morbidity and 
mortality in kidney 
failure 
Lower dialysis dose, 
temporary vascular access, 
anemia, low serum albumin 
level, late referral 
 Patient diagnosed with severe renal impairment and patient in dialysis are 
followed closely by nephrologist in specialized nephrology department. The high 
prevalence of renal failure and the large number of drugs with renal elimination or 
potential nephrotoxicity suggest that physicians should consider renal function 
when prescribing. Studies have suggested that care provided by multi-disciplinary 
nephrology teams may improve patient outcome. However, in most patients with 
mild to moderate RI the reduced function may not have been diagnosed and these 
patients are managed in general practice and in general hospitals. The necessity of 
dose adjustment or drug avoidance is probably under estimated in clinical 
practice.8 
Introduction 
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INITIATION AND PROGRESSION OF CHRONIC KIDNEY DISEASE 
(CKD) AND THERAPEUTIC INTERVENTIONS.7 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
LABORATORY EVALUATION OF RENAL FUNCTION 
 Kidney function is assessed by a variety of tests and procedures that can be 
done to evaluate how well kidneys are functioning. These tests are done on urine 
as well as blood samples. Many conditions can affect the ability of the kidneys to 
carry out their vital function. The extent of loss of renal function is judged by 
calculating creatinine clearance which is a useful measure of glomerular filtration 
rate. According to the reduction in creatinine clearance value the patients are 
categorised into mild moderate and severe renal impairment. 
The standard indicators of renal function are serum levels of urea nitrogen 
and creatinine: this ratio is normally about 10:1. This ratio may increase when 
renal perfusion or urine flow is decreased, as in the urinary tract obstruction or 
dehydration. The most reliable single indicator of glomerular function is serum 
levels of creatinine. For example serum creatinine increasing from 0.5mg/dl to 
1mg/dl represents 50% reduction in GFR. 
Introduction 
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 Serum creatinine is a by-product of creatinine metabolism in 
muscle. It is filtered in the glomeruli, but not reabsorbed in the tubules. Therefore, 
blood values depend closely on GFR. Normal creatinine level is proportional to 
muscle mass. For example, small woman – 0.5mg/dl, man – 1mg/dl and muscular 
man – 11.4mg/dl 
 If value doubles, GFR and renal function probably have fallen to half of 
normal state. 
 If value triples, it suggested 75% loss of renal function. 
 Values of 10mg/100ml suggests 90% loss of renal function  
Creatinine clearance: For 24 hours urine. Normal results: 90-139ml/min for 
adults and 80-125ml/min for females.9 
The NKF-KDOQI clinical practice guideline advocates using the 
traditional Cockcroft - Gault equation or Modification of Diet in Renal Disease 
(MDRD) study equation for routine estimation of GFR. However, in patients with 
a GFR lower than 60ml/min/1.73m2 the MDRD equation has been shown to be 
superior to the Cockcroft - Gault equation. 
Because the production and excretion of creatinine declines with age, 
normal serum creatinine values may not represent normal renal function in older 
patients. The MDRD equation has been shown to be the best method for detecting 
a GFR lower than 90ml/min/1.73m2     5 
Renal drug clearance 2 
Three processes that can potentially contribute to the renal clearance of a 
drug are glomerular filtration, tubular secretion and tubular reabsorption. 
Approximately 20 -25 % of cardiac output or 1.1L of blood per min goes to the 
kidneys. Of this volume, approximately 10% is filtered at the glomerulus. Large 
circulating molecules, such as albumin and α1- acid glycoprotein to which many 
drugs are reversibly bound, are normally not filtered to any appreciable extent at 
the glomerulus. Consequently, only unbound drug in plasma water is excreted by 
glomerular filtration. Glomerular filtration is a low clearance process.  
Introduction 
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 Active tubular secretion is another efficient mechanism for 
extracting substances from the circulation and secreting them into the tubular 
lumen. Renal clearance by tubular secretion can be perfusion rate limited or 
capacity rate limited. The renal proximal tubule is the primary site of active 
transport for a wide variety of substrates including organic anions/ cations, 
peptides and nucleosides. 
 Tubular reabsorption, which takes place by passive diffusion, may 
also influence the renal excretion of drugs. The extensive reabsorption of filtered 
water along the renal tubule- from 120 ml of plasma water filtered per min to only 
1 to 2 ml/min arriving in the collecting tubules and bladder as urine is a driving 
force for to tubular reabsorption. Factors that control the tubular reabsorption of 
drugs are urine pH, degree of ionisation of drugs and their metabolites, urinary 
flow rate, lipophilicity and pKa. 
Effect of renal dysfunction on pharmacokinetic process2 
Absorption 
 Drugs are most frequently administered orally. Both the rate and extent of 
absorption from the GI tract influence the drug plasma concentration- time profile. 
The rate of absorption is assessed by measuring Tmax, the time at which the 
maximum plasma concentration (Cmax) occurs. Tmax has been shown to be 
slightly increased for a number of drugs when administered orally to patients with 
severe renal dysfunction. The longer Tmax may be due to reduced gastric emptying 
in these patients or simply to a longer plasma elimination half-life of the drug.  
Extent of oral absorption is best assessed by comparing the area under the plasma 
drug concentration- time curve (AUC) following oral and IV administration. In 
patients with renal dysfunction do not measure absolute oral bioavailability but 
simply determine pharmacokinetic parameters such as plasma clearance, Vd and 
plasma half-life following oral administration of the drug. Patients with renal 
disease are treated with many medications some of which may alter the absorption 
of other concomitantly administered drugs. For example hyperphosphatemia is an 
important component of the bone disease seen in chronic renal failure and many 
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of these patients take phosphate binders may interact with certain drugs like 
fluroquinolones, thereby reducing their extent of absorption. 
Distribution 
 The plasma protein binding of many acidic drugs is decreased in patients 
with renal dysfunction. Several mechanisms decreased plasma binding, including 
hypoalbuminemia, the accumulation of endogenous substances which 
competitively displace acidic drugs from their binding sites on albumin, and a 
conformational change of the binding sites on the albumin molecule. While 
acidic drugs usually bind to plasma albumin, basic drugs in general have a high 
affinity for α1-acid glycoprotein but often also bind to albumin and lipoproteins. 
Although the plasma binding of basic drugs appears to be generally unaffected in 
patients with chronic renal disease, it may be increased for some drugs (e.g., 
bepridil, disopyramide) because α1-acid glycoprotein is an acute phase protein 
that is elevated in certain patients with renal disease, such as in renal transplant 
patients and patients on haemodialysis. 
 The volume of distribution of several drugs is significantly increased in 
patients with severe renal dysfunction. An increased volume of distribution may 
be the result of fluid overload, decreased protein binding, or altered tissue 
binding. The volume of distribution of a few drugs, such as digoxin, pindolol, 
and ethambutol, is decreased in patients with ESRD probably due to a decrease 
in their tissue binding. 
Metabolism 
Drugs which are mostly or completely eliminated from the body by non- 
renal mechanisms may accumulate in patients with renal dysfunction if their 
dosage regimen is not adjusted. Pharmacokinetic studies in patients with renal 
dysfunction have shown that non-renal clearance is reduced for many drugs, 
especially in ESRD, providing indirect evidence that the metabolism of these 
drugs is impaired in these patients. Recently, the effect of renal dysfunction 
on drug-metabolizing enzymes has been directly demonstrated. Dowling et al. 
Introduction 
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used the erythromycin breath test (EBT) to assess hepatic CYP3A activity in 
patients with ESRD undergoing long-term hemodialysis three times weekly. 
The EBT following intravenous administration of C-erythromycin has been 
extensively used to measure in vivo hepatic cytochrome 450 (CYP)3 A activity, 
although the outcome of the test may also be affected by the activity of hepatic 
uptake and efflux transporters such as OATP and P-gp. The results of this study 
showed that patients with ESRD had a 28% lower base line hepatic EBT value 
despite adequate dialysis compared to age-matched healthy control subjects. 
Likewise, Dreisbach et al. measured the plasma warfarin S/R ratio in patients 
with ESRD. The idea that renal dysfunction could differentially affect the 
activity of various drug- metabolizing enzymes. A study reveals that, although 
the overall plasma clearance of antipyrine, amarker substance completely 
eliminated by metabolism catalyzed by several CYP450 isoenzymes, was not 
different in patients with chronic renal failure compared to healthy control 
subjects, the formation clearance of one of the metabolites, nor antipyrine, was 
decreased on average by 50% in the renal patients. 
Many in vivo and in vitro studies on acute and chronic renal failure 
subjects, it shows a down-regulation of the activity of not only CYP450 
enzymes but also other drug-metabolizing enzymes, such as N-acetyl 
transferase. In contrast, the activity of UDP- glucuronosyl transferases 1A and 
2B seem to be preserved. Uremic toxins that accumulate in the body in chronic 
renal failure have been implicated in these alterations in drug-metabolizing 
enzyme activity. 
Many drugs and/or their phase I metabolites are eliminated by 
glucuronidation. These glucuronides are very polar and are efficiently 
excreted by r en a l  mechanisms such as tubular secretion. Acyl glucuronides, 
i.e., glucuronide conjugates of compounds containing a carboxylic acid group, 
are not stable at physiological pH and are susceptible to hydrolysis by amyriad 
of catalysts, including β-glucuronidases, non-specific esterases, serum albumin, 
and hydroxideions. In patients with renal dysfunction, glucuronide conjugates 
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generally accumulate in the plasma. In the case of plasma accumulation of acyl 
glucuronides of carboxylic acid drugs, this will inevitably lead to their systemic 
hydrolysis and, consequently, reduced plasma clearance of the parent 
compound. Systemic hydrolysis of acyl glucuronides has been shown to be the 
cause of accumulation of several carboxylic acid drugs in patients with renal 
dysfunction. For example, the aryl propionic acid non-steroidal anti-
inflammatory drug ketoprofen has a significantly reduced plasma clearance in 
patients with renal dysfunction because of the compromised capacity to excrete 
ketoprofen acyl glucuronide in urine which results in enhanced regeneration of 
the parent drug by hydrolysis. 
 Impaired drug metabolism has been shown in patients with severe renal 
dysfunction (see below) and may be the cause of a significant increase in oral 
bioavailabity in these patients due to reduced presystemic elimination. One of the 
first well- documented examples of increased plasma drug concentrations due to 
decreased first-pass metabolism is propoxyphene. Propoxyphene is subject to 
pronounced pre- systemic biotransformation after oral administration. In 
functionally anephric patients, the AUC of propoxyphene and its major 
metabolite, nor pro-poxyphene, was shown to be approximately two fold higher 
than that of healthy control subjects. The increase in the AUC of propoxyphene is 
very likely the result of reduced pre-systemic metabolism in the anephric patients. 
Nor pro- poxyphene is normally eliminated renally and, therefore, accumulates 
when renal function is impaired. Like pro- poxyphene, nor-propoxyphene can 
depress cardiac conduction, and its accumulation can contribute to the cardiac 
toxicity. 
Accumulation of active metabolites: 
 Many drugs are eliminated from the body by metabolism. The metabolites 
thus formed are often thought of as inactive waste products, which is certainly 
not always the case. In many other cases, both the parent compound and its 
metabolite(s) are active. The duration and intensity of the pharmacological 
responses are dependent on the time course so fall active substances in the 
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body. Drug metabolites are usually eliminated by further metabolism and/or 
renal excretion. Consequently, metabolites, especially polar phase II conjugates 
such as glucuronides and sulfates, often accumulate in patients with renal 
dysfunction. When adjusting the dosage of a drug in these patients, the altered 
pharmacokinetics of all active species of the drug molecule has to be considered. 
 Morphine is a good example illustrating the significance of the 
accumulation of drug metabolites in patients with renal dysfunction. 
Elimination 
 Metabolism is the major mechanism for the elimination of drugs from the 
body. Relatively few drugs are eliminated almost entirely unchanged by the 
kidneys. The plasma clearance of a drug is the pharmacokinetic parameter that 
best describes the capacity of a patient to eliminate that drug substance. Drug 
plasma clearance (CL) is generally considered to be the sum of a renal and non-
renal component. 
Renal Excretion 
 Depending on the etiology of renal dysfunction, the normal histology of 
the glomeruli and the tubules may be differentially affected. However, according 
to the intact nephron hypothesis, the function of all segments of a diseased 
nephron is assumed to be equally affected. Consequently, it is assumed that, 
regardless of the intra renal path ways of excretion, i.e., filtration, secretion, and 
reabsorption, the loss of excretory function in the diseased kidney can be 
quantified by GFR, a measure of glomerular function. Although it has been shown 
in rat models of acute renal failure that glomerular filtration and tubular secretion 
by the anionic and cationic pathways are not equally affected, the renal clearance 
of most drugs in patients appears to vary indirect proportion to GFR or to a 
measure of GFR, such as estimated creatinine clearance, regardless of the intra 
renal mechanism involved in their urinary excretion. For example, the plasma 
clearance of memantine has been shown to increase indirect proportion to CLCR, 
as estimated by the Cockroft–Gault method. When there is no renal function, 
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some plasma clearance remains: this is the non-renal clearance. Dosage 
adjustment of memantine in patients with impaired renal function will be based 
on the relationship between memantine plasma clearance and CLcr in the studied 
patient sample. As pointed out before, the intact nephron hypothesis has been 
questioned by some researchers who believe that a better method to quantify renal 
function for dosage adjustment purposes may be based on the cocktail approach. 
 
Altered pharmacodynamics in renal disease 2 
Chronic renal failure can affect multiple organ systems and, the response 
to a given drug may change even though the drug’s pharmacokinetics is not 
dramatically altered. For example, furosemide reaches its site of action via tubular 
secretion. Patients with chronic renal failure exhibit an increased maximal 
response when the dose is adjusted to the functional status of the kidneys. To 
achieve an adequate diuretic response, plasma furosemide concentrations must be 
in- creased by administering larger doses so that adequate amounts of drug reach 
the site of action. Adjusting the furosemide dose in a patient with renal 
dysfunction to maintain normal plasma concentrations would not be appropriate 
because of the altered pharmacodynamic response of furosemide in chronic renal 
failure. 
Several studies of enoxaparin in patients with varying degrees of renal 
failure have shown that anti-Xa clearance decreases with the degree of renal 
function. As a result, dosage reduction is recommended in patients with severe 
renal impairment (i.e., ClCr<30mlmin−1). 
 The effect of renal dysfunction on the pharmacodynamics responses of 
drugs has not been well studied. However, the examples of furosemide and 
enoxaparin show that ideally integrated PK/PD studies are needed to evaluate the 
necessity of dosage adjustment in renal dysfunction. 
Principles of Dose Adjustment in Renal Impairment 2 
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 The level of renal function below which the dose of a drug must be 
reduced depends on the proportion of a drug eliminated by renal excretion and its 
toxicity. 
 For many drugs with only minor or no dose related side effects very 
precise modification of the dose regimen is unnecessary and a simple scheme for 
dose reduction is sufficient. 
 For more toxic drugs with a small safety margin dose regimens based on 
glomerular filtration rate should be used. When both efficacy and toxicity are 
closely related to plasma – drug concentration, recommended regimens should be 
regarded only as a guide to initial treatment. Subsequent doses must be adjusted 
according to clinical response and plasma – drug concentration. 
 Renal failure declines with age, many elderly patients have renal 
impairment but, because of reduced muscle mass, this may not be indicated by a 
raised serum creatinine. It is wise to assume at least mild impairment of renal 
function when prescribing for the elderly. 
 The total daily maintenance dose of a drug can be reduced either by 
reducing the size of the individual doses or by increasing the interval between 
doses. For some drugs, although the size of the maintenance dose is reduced it is 
important to give a loading dose if an immediate effect is required. This is because 
it takes about five times the half – life of the drug to achieve steady – state plasma 
concentrations. Because the plasma half – life drugs excreted by the kidney is 
prolonged in renal impairment it can take many doses for the reduced dosage to 
achieve a therapeutic plasma concentration. The loading dose should usually be 
the same size as the initial dose for a patient with normal renal function. 
Nephrotoxic drugs should, if possible, be avoided in patients with renal disease 
because the consequences of nephrotoxicity are likely to be more serious when 
renal reserve already reduced. 
 
Dosage Adjustment in Patients with Renal Dysfunction 
 Adjustment of the usual drug dosage regimen may be necessary in 
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patients with renal dysfunction to avoid excessive accumulation of the drug 
and/or its active metabolite(s) which could result in serious adverse reactions. 
A dosage regimen is characterized by the maintenance dose (DM) and the 
dosing interval (τ). The goal is to derive an equation that allows estimation of 
the maintenance dosing regimen in a patient with renal dysfunction based on a 
measure of his/her kidney function (KF). The objective is to adjust the usual 
dosage regimen, by reducing the maintenance dose and/or prolonging the 
dosing interval, to avoid accumulation of the drug (and/or its active 
metabolites) in the patient with impaired kidney function. 
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LITERATURE REVIEW 
 
        Md Aslam Ali Hashmi et al54 (2017) performed a study on Antibiotics 
requiring dosage adjustment in community acquired pneumonia patients with 
renal impairment. A prospective and observational study was carried out in a 
Tertiary care hospital. All community-acquired pneumonia patients with mild to 
moderate renal impairment were included. The Cockroft-gault formula or MDRD 
equation was used to calculate creatinine clearance. The mean creatinine clearance 
values were calculated by t-test and chi-square test was used to test categorical 
variables. The odds ratio and relative risk were estimated to test the association 
between antibiotics requiring dosage adjustment and mortality. The proportions of 
antibiotics requiring adjustment in Community acquired pneumonia patients with 
renal impairment were high in the present study. It was concluded that large 
randomized studies particularly focusing on in-hospital mortality of the patients 
with renal impairment is warranted. 
        Alok Kumar et al55 (2016) performed a study on Evaluation of Antibiotic 
Dose Adjustment in Patients with Renal Insufficiency in a Tertiary Care Centre. 
The study is retrospective and cross sectional. Records of all patients with renal 
dysfunction in any department where nephrology unit was consulted were 
screened. Inclusion criteria were eGFR of < 60ml/minute, age>16 years and 
administration of at least 1 antibiotic. Prescribed dosage of the drug was compared 
with dosage recommended by guidelines to assess appropriateness of dose in renal 
dysfunction. GFR was calculated by Cockcroft Gault equation. This study showed 
that there was no adjustment done in drug doses in 63% patients with renal 
insufficiency and 23.9% got adjustment for some drugs. 24 patients (9.9%) 
developed adverse drug reaction attributable to excessive doses. There is need to 
create awareness among physicians for drug dose adjustment in renal dysfunction. 
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         Henok Getachew et al49 (2015) performed a study on Drug dosage 
adjustment in hospitalized patients with renal impairment at Tikur Anbessa 
Specialized hospital, Addis Ababa, Ethiopia. A prospective cross-sectional study 
was carried out in the internal medicine wards. All patients with creatinine 
clearance ≤59 ml/min admitted to hospital between April and July, 2016 were 
included in the analysis. The estimated creatinine clearance was calculated using 
the Cockcroft- Gault (CG) equation. Guideline for Drug prescribing in renal 
failure provided by the American College of Physicians was used as the standard 
for dose adjustment. The findings indicate that dosing errors were common among 
hospitalized patients with renal impairment. Improving the quality of drug 
prescription in patients with renal impairment could be of importance for 
improving the quality of care. 
        Fanak Fahimia et al50 (2012) determined the number of prescribed 
antibiotics being adjusted and assessed dosing of antibiotics based on the patient’s 
renal function according to distinguished guidelines. The study was conducted at a 
446-bed university hospital. One hundred and fifty patients admitted through 
different wards of the hospital were included in the study. Demographic data were 
extracted and creatinine clearance was calculated using either Cockcroft- Gault 
(C&G) or Modification of Diet in Renal Disease (MDRD) formula. In patients 
with creatinine clearances less than 50 mL/min, antibiotic dosages were compared 
with guideline dose recommendations to judge whether they were correctly 
adjusted. Two hundreds and ninety-one instructions (79.9%) of 364 antibiotic 
prescriptions required dosage adjustment based on the patient’s renal condition. 
These adjustments were rationally performed in 43.7% and 61.4% of 
prescriptions, according to the two guidelines used. Ciprofloxacin (29.1% of 
cases), and vancomycin (33.6% of cases), were the most inappropriately 
prescribed antibiotics in terms of dose administration, and concluded that the drug 
dosing adjustments should be emphasized in patients with renal dysfunction. 
Failure to do so may lead to higher morbidity and mortality as well as therapeutic 
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costs. Estimating creatinine clearance prior to drug ordering and use of a reliable 
dosing guideline is highly recommended. 
           Abdul rah man M51 (2012) the study was conducted to determine whether 
dose adjustment was taken into account or not when prescribing drugs in patients 
with renal impairment. A retrospective chart review was performed and included 
98 adult in-patients, diagnosed with renal impairment based on clinical evaluation 
and laboratory data, in King Abdul-Aziz University Hospital (KAUH), Jeddah, 
Saudi Arabia, who was admitted to the hospital from September 2005 to January 
2011. Data of the patients were noted and recorded including baseline 
demographics, clinical data, laboratory data, renal state, treatment data and 
medications. The current study confirms that dosage adjustment has to be done for 
renal impairment when prescribing drugs. Continuous medical education and 
collaboration with clinical pharmacist should be encouraged for quality 
improvement in patients with renal impairment. 
           Sepideh Emami, Hamid Riazi Esfahani52 (2012) conducted the present 
observational study was performed on drugs requiring dose adjustment in kidney 
disease to assess the frequency and potential consequences of overlooked dosage 
adjustment in hospitalized patients. Medication records and data of 142 patients 
were collected on random basis. Selected patients with elevated serum creatinine 
who were prescribed at least one drug needing dose adjustment were kept for 
further study. Eight hundred and thirty drug orders were evaluated in which dose 
adjustment was required in 193 (23.2%) of cases. Proper dose adjustments were 
performed in 88 (45.5%) of cases and not performed in 105(54.4%) orders. 
According to the study, dose adjustment in renal dysfunction shows a great need 
for pharmacist involvement in the process to improve drug dosing and avoid 
adverse drug reactions. Sub-grouping patients according to kidney function and 
following established dosing guidelines is recommended. 
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          Alahdal and Ahmed10 (2011) determined whether appropriate dose 
adjustment was taken into account or not by the physicians when prescribing drug 
in patients with renal impairment. Retrospective study was performed which 
includes 98 adult in-patients, diagnosed with renal impairment based on clinical 
evaluation and laboratory data. 502 drugs were investigated in the present study 
with an average of six drugs per patient. Of these 502 drugs, 196(39%) required 
dose adjustment where 92(46.9%) were adjusted and 104(53.1%) were not 
adjusted. So this study confirms that physicians still do not take into account 
sufficiently patient’s renal function when prescribing drugs. Continuous medical 
education with clinical pharmacist should be encouraged for quality improvement 
in patients with renal impairment. 
           Verbeeck and Flora2 (2009) described about the pharmacokinetics and 
dosage adjustment in patients with renal dysfunction. In patients with kidney 
dysfunction, the activity of several drug metabolizing enzymes, drug transporters 
and the renal excretion of parent drug and/or its metabolites will be impaired, 
leading to their excessive accumulation in the body. In addition the plasma protein 
binding of drugs may be significantly reduced which in turn could influence the 
pharmacokinetic processes of distribution and elimination. In a patient with renal 
dysfunction the normal dosage regimen of a drug should be adjusted to get 
therapeutic effects. Dosage adjustment was estimated on the basis of GFR 
(glomerular filtration rate) or CrCl (creatinine clearance) using MDRD 
(modification of diet in renal disease) or Cockroft-Gault formula. Thus this study 
stated that a pharmacokinetic study should be carried out during the development 
phase of a new drug that is likely to be used in patients with renal dysfunction and 
appropriate dosing should be done to reduce toxicity and to get effective therapy. 
           Hassan et.al.11 (2008) studied the rate of inappropriate dosing in patients 
with CKD in a nephrology unit and evaluated the impact on dose adjustment; 
adverse drug events and drug cost. The authors suggested that appropriate drug 
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selection and dosing for patients with chronic kidney disease is important to avoid 
unwanted drug effects and ensure patient outcomes.  
            Libiszewski12 (2008) described the development of a drug dosage 
adjustment service for patients with renal impairment. The dosage of nephrotoxic 
drugs such as gentamicin should ideally be adjusted when they were administered 
to patients with varying degrees of renal impairment. Such an adjustment of 
dosage should be estimated with a knowledge of the plasma levels of the drug. 
Until regular monitoring of drug levels in plasma was routinely available. A 
service for dosage adjustment of nephrotoxic drugs had been provided in the 
Macclesfield Health District since December 1977 and has been well received by 
prescribers in the hospitals. The use of a flow chart scheme for the adjustment of 
individual dosage for routine use is described. About 80% of the requests were for 
dosage adjustments of gentamicin in renal failure. It is advocated that such a 
service can be provided by hospital pharmacists without difficulty and should be 
encouraged as part of the patient services. 
 Roblin et al13 (2008) evaluated if Cockcroft and Gault (CG) estimated 
glomerular filtration rate (eGFR) might be replaced by abbreviated MDRD eGFR 
for drug dose adjustment. CG eGFR was 61 mL/min vs. 78 mL/min/1.73 m2 for 
MDRD (p < 0.0001). CG-MDRD difference ranged from − 93 to + 34 mL/min, 
influenced by patient age, weight, and gender (p < 0.001). Authors suggested that  
CG eGFR cannot be easily replaced by abbreviated MDRD eGFR for drug dose 
adjustment12. 
Philipneri et al14 (2008) developed a guideline for management of chronic 
kidney disease (CKD). K/DOQI-consistent measurements of parathyroid hormone 
(7.1 vs. 0.6%, P = 0.0002), phosphorus (38.2 vs. 1.9%, P < 0.0001) and quantified 
urinary protein (23.8 vs. 9.4%, P = 0.008) were more common among CKD 
patients with or without nephrology referral in the administrative 
data. Nephrology referral correlated with increased likelihood of testing for 
parathyroid hormone and phosphorus after adjustment for baseline patient factors. 
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Use of ACEi/ARB medications was more common among patients with 
nephrology contact (50.0 vs. 30.0%; P = 0.008) but appeared largely driven by 
higher comorbidity burden. The literature review demonstrated similar practice 
patterns. Authors concluded that Delivery of CKD care may be monitored by 
administrative data. There was any opportunity for improvement in CKD 
guideline adherence in practice. 
 Munar et al5 (2007) reported dosing errors are common in patients with 
renal impairment and can cause adverse effects and poor outcomes. Dosages of 
drugs cleared renally should be adjusted according to creatinine clearance or 
glomerular filtration rate and should be calculated using online or electronic 
calculators. Recommended methods for maintenance dosing adjustments are dose 
reductions, lengthening the dosing interval, or both. Physicians should be familiar 
with commonly used medications that require dosage adjustments. Resources are 
available to assist in dosing decisions for patients with chronic kidney disease. 
 Cavanaugh15 (2007) mentioned that Chronic kidney disease (CKD) was 
common and can be found in up to 23% of patients with diabetes. The 
recommended haemoglobin A1C goal for these patients is also < 7.0%. 
Medication therapy for diabetes may require dose adjustments or may be 
contraindicated in patients with CKD. Assessment and management of comorbid 
diseases, including hypertension, hyperlipidemia, anemia, hyperphosphatemia, 
and hyperparathyroidism, was important in the care of patients with diabetes and 
CKD. Multidisciplinary care may provide the optimal system for maximizing care 
of these complex patients. 
 Marr16 (2007) prepared a guideline for Antibiotic dosing in renal 
impairment. 
 Shyam et al17 (2007) reported the need of national action plan for 
minimizing the progression of CKD. Author suggested that a Government-
supported programme should be initiated for the large expanding ESRD 
population. Simultaneously efforts should be made to plan and initiate a 
Literature Review 
 
 
 
 
 
 
Dosage individualization of anti microbials and cardiovascular drugs in patients with chronic 
renal dysfunction                                                                                                        P a g e  | 27 
prevention/control program for CKD. To pick up CKD at an early stage, steps 
should be initiated to promote methodology for standardization and estimation of 
glomerular filtration rate (GFR) rather than serum creatinine in clinical 
laboratories. Such data would prompt and enable physicians to pick up CKD at an 
earlier stage, improve the opportunity for early referral of CKD patients to 
nephrologists to minimize progression of CKD. 
 Blix et al4 (2006) investigated the use of renal risk drugs in renally 
impaired patients in general hospitals and analysed the relationship to 
demographic factors, risk factors and occurrence of drug-related problems. Of the 
808 included patients, 293 (36%) had normal renal function (stage 1), 314 (39%) 
had mild RI (stage 2), 160 (20%) had moderate RI (stage 3), 35 (4%) had severe 
RI (stage 4) and six (0.7%) had kidney failure (stage 5). Mean number of drugs 
used per patient in patients with RI (stages 3, 4 and 5) and patients evaluated to 
have adequate renal function relative to drug therapy (stages 1 and 2). All but six 
patients with RI stages 3, 4 and 5 used two or more renal risk drugs. 124 (62%) of 
the patients with RI stages 3, 4 and 5 had DRPs linked to the renal risk drugs, and 
26% of the renal risk drugs were associated with DRPs. In patients with reduced 
renal function, renal risk drugs were widely used and often in combination. DRPs 
were frequently associated with the use of renal risk drugs. 
 Dijk et al18 (2006) analysed the incidence of required versus implemented 
dosage adjustments according to guidelines in patients with renal insufficiency at 
discharge and evaluated specific determinants responsible for the percentage of 
overlooked dosage adjustments. At discharge, 237 of 647 (36.6%) patients had a 
calculated creatinine clearance less than 51 mL/min/1.73 m2. Dosage adjustment 
based on renal function was necessary in 411 of 1718 (23.9%) of prescriptions. 
These adjustments were performed in 242 (58.9%) prescriptions and not 
performed in 169 (41.1%) cases. The risk of not adjusting the dosage was 
significantly associated with drugs producing severe consequences when dosing 
guidelines were overlooked (p < 0.05). In patients with a calculated creatinine 
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clearance less than 51 mL/min/1.73 m2, dosing according to their renal function 
can be improved; an alert system could help prescribers and pharmacists to adapt 
drug dosage in patients with renal impairment. 
 Joshi9 (2006) marked variability in drug responsiveness especially in 
critically ill patients admitted in the Intensive care units. In order to obtain 
therapeutic effectiveness with in pharmacokinetic parameters related to 
therapeutic dose, it is always desirable to monitor and to maintain drug dose 
adjustment in such a way especially in presence of organ failure like renal failure, 
hepatic failure or any other clinical situation necessitating Therapeutic Drug 
Monitoring (TDM) so that one can use safe and effective drug therapy with least 
toxicity due to inaccurate and invalid drug doses. 
 Levey et al19 2006 described the performance of the revised 4-variable 
MDRD Study equation and compare it with the performance of the 6-variable 
MDRD Study and Cockcroft–Gault equations. Mean measured GFR was 39.8 
mL/min per 1.73 m2 (SD, 21.2) Accuracy and precision of the revised 4-variable 
equation were similar to those of the original 6-variable equation and better than 
in the Cockcroft–Gault equation, even when the latter was corrected for bias, with 
90%, 91%, 60%, and 83% of estimates within 30% of measured GFR, 
respectively. Differences between measured and estimated GFR were greater for 
all equations when the estimated GFR was 60 mL/min per 1.73 m2 or greater. The 
4-variable MDRD Study equation provides reasonably accurate GFR estimates in 
patients with chronic kidney disease and a measured GFR of less than 90 mL/min 
per 1.73 m2. 
 Vidal et al20 (2005) compared four sources of drug information regarding 
adjustment of dose for renal function. The four sources differed in their 
recommendations for adjustments of dosage and dosing interval. They vary in 
their definitions of renal impairment; some were qualitative and remain unclear. 
All sources provide only a general description; the methods on which the advice is 
based and references for original data are rarely presented. The remarkable 
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variation in definitions and recommendations, along with scarce details of the 
methods used to reach this advice, maid the available sources of drug information 
ill-suited for clinical use. Authors noted that advice on drug prescription, dose and 
dosing interval, contraindications, and adverse effects should be evidence based. 
 Ricci et al21 (2005) observed the practice patterns in the management of 
acute renal failure in the critically ill patient. More than 200 different definitions 
of ARF and about 90 RRT start criteria were reported. In 10% of centres all forms 
of renal replacement techniques were available, and in 70% of cases two or more 
different techniques were available: absolute analysis of different techniques 
showed that continuous renal replacement therapies were utilized by 511 
specialists (91%), intermittent haemodialysis by 387 (69%) and sustained low 
efficiency dialysis by 136 (24%). Treatment prescription showed significant 
differences among specialists, 60% of intensives being uncertain on RRT dose 
prescription compared to 40% of nephrologists (P = 0.002). New 
classifications such as RIFLE criteria might improve well-known 
uncertainty about ARF definition. Different RRT techniques are available in most 
centres, but a general lack of treatment dose standardization is noted. Non-renal 
indications to RRT still need to find a definitive role in routine practice. 
 Ararwal et al22 (2005) mentioned that Chronic renal failure (CRF) is a 
debilitating condition responsible for high morbidity and mortality and was a 
financial burden on government and society. Because of its costs and the 
complexity of its treatment, proper care is available to very few patients in India. 
A community-based study has not been done to determine the prevalence of CRF 
in India. Results. A total of 4972 persons were contacted for the study. Their mean 
age was 42±13 years; 56% were males. Out of the 4972 who were initially 
approached, 4712 agreed to give the blood sample, and thus were included for the 
evaluation of CRF. CRF was found in 37 of them. Thus, the prevalence of CRF in 
that adult population was 0.785% or 7852/million. In conclusion, the prevalence 
of CRF in India makes it a serious problem in need of urgent efforts to control it. 
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 Bailie et al23 (2004) evaluated the analgesic prescription patterns among 
hemodialysis patients. Our results highlight that analgesics may be 
underprescribed in the hemodialysis population. With respect to prevention of 
chronic kidney damage, the National Kidney Foundation's position paper suggests 
acetaminophen as the nonnarcotic agent of choice for episodic use, although 
habitual use, and use of combination analgesic products, should be discouraged. It 
is possible, although uncertain, that this recommendation has lead to a more 
cautious use of analgesics in general in patients with kidney disease and resulted 
in potential under-prescription. The safest approach to the management of pain in 
dialysis patients may be the use of short courses of analgesics, where possible. 
Extra vigilance is warranted for potential adverse effects of all analgesics in 
dialysis patients. The extreme variability in facility practice suggests that patients 
and clinicians should be educated about the need to appropriately prescribe 
analgesics. Patients should understand that optimal pain management was an 
acceptable expectation, and clinicians should examine reasons for any reluctance 
on their part to prescribe analgesics. The refinement of existing World Health 
Organization guidelines regarding analgesic use in dialysis patients may be 
necessary to improve pain management and quality of life for this population. 
Changes might be necessary to reflect appropriate choices of analgesics, 
statements about combination products, and perhaps education about methods for 
assessment of appropriate analgesia. 
  Nurko25 (2004) published Seventh Report of the Joint National 
Committee on the Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure. Most patients with advanced chronic kidney disease (CKD) 
develop hypertension. Most classes of antihypertensive medication can be used to 
treat patients with CKD. The general approach for prescribing drugs in CKD had 
been either to decrease the maintenance dose without changing dosing intervals, 
or to keep the usual dose but prolong the dosing intervals, or use of a combination 
of these interventions. Each drug should be evaluated individually. 
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 Manley et al26 (2004) compared  haemodialysis (HD) patient medication 
prescribing patterns between the Dialysis Clinic, Inc. (DCI) database and the 
United States Renal Data System report. There were 128 477 medication orders 
categorized in 10 474 patients. DCI patient demographics were similar to 
present USRDS patients except for fewer Hispanics (P<0.001). Patients were 
prescribed 12.3±5.0 (median 12) different medications (2.6±1.4 clinic medications 
and 10.0±4.5 home medications). This is higher than reported by USRDS 
(median 9 medications). Patient age did not influence number of medications  used 
(P = 0.54). DM patients were prescribed more medications than non-DM 
(13.3±5.0 DM vs 11.6±4.8 non-DM; P<0.00001). The data suggested that 
medication prescribing patterns in HD patients have changed. The audit identified 
appropriate and questionable prescribing patterns. Various prescribing patterns 
identified areas for improvement in care (e.g. increased use of aspirin, beta-
blockers and hyperlipidaemia medications) and areas requiring further 
investigation (e.g. high use of anti-acid, benzodiazepine and non-aluminum/non-
calcium phosphate-binding medications). 
 Salamon et al41 (2003) determined the frequency and potential 
consequences of lack of dosage adjustment in hospitalized patients with renal 
impairment. 202 order sheets were completed for 164 patients. They totalled 1469 
lines of prescription, 85% of which were TEM medications, with guidelines for 
dosage adjustment for 71% of them (n=886). Of these 886 prescriptions, 34% 
were inappropriate, 14% being contraindicated and 20% with inappropriate 
dosage given the patient’s renal function. Among the 202 order sheets, 75% 
included at least one appropriate prescription. 63% included at least 1 prescription 
with potentially adverse consequences, 3% of these had potential fatal or severe 
consequences. The study confirmed that physicians do not take into account 
sufficiently patient renal function when prescribing. Improving the quality of drug 
prescription in patients with renal impairment could be of importance for 
improving the quality of life. 
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 Levey et al7 (2003) evaluated the usage of the Guidelines for Chronic 
KidneyDisease: Evaluation, Classification, and Stratification in US population and 
reported that Chronic kidney disease affects approximately 11% of the U.S. adult 
population (20 million people from 1988 to 1994). The prevalence of earlier 
stages of disease (10.8%) is more than 100 times greater than the prevalence of 
kidney failure (0.1%). Adverse outcomes of chronic kidney disease, including loss 
of kidney function and development of kidney failure and CVD, can often be 
prevented or delayed through early detection and treatment. In particular, 
physicians should consider using interventions to slow the progression of kidney 
disease in all patients with chronic kidney disease and should place patients with 
chronic kidney disease in the highest-risk group for CVD risk factor reduction and 
other treatments for CVD.  
 Pillans et al27 (2002) observed whether appropriate dosage adjustments 
were made in patients with significant renal impairment for drugs with a high 
fractional renal clearance. Doses were found to be inappropriately high in 105 
(42.2%) of 249 admission prescriptions of the targeted drugs. Doses were 
appropriately reduced in hospital in 32 patients (30.4%). Seventy-three (29.3%) 
prescriptions were continued with excessive doses. Only 34 prescriptions for the 
target drugs were initiated in hospital, of which 88.2% were appropriately dosed. 
A significant percentage of patients with renal impairment are admitted to hospital 
on inappro priately high doses of drugs, with a high fractional renal excretion and 
low therapeutic index. Doses are appropriately reduced in hospital in some 
patients but there is still room for improvement. 
 Falconnier et al8 (2001) examined the impact of immediate concurrent 
feedback on dose adjustment in patients with renal failure. Overall, 17% of the 
patients had atleast 1 estimated creatinine clearance 50 mL/min. In the 
intervention group, the dose of 81% of renally eliminated drugs was adjusted to 
renal function, compared with 33% in the control group. The propotion of doses 
renally eliminated drugs adjusted to renal function can be substantially increased 
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by immediate concurrent feedback. This saves drug costs and has the potential to 
prevent adverse drug reactions. 
 Chertow et al28 (2001) explained a system application for adjustment for 
dose and frequency in patients with renal insufficiency. A total of 7490 patients 
were found to have some degree of renal insufficiency. In this group, 97151 
orders were written on renally cleared or nephrotoxic medications, of which 
14440 (15%) had at least 1 dosing parameter modified by the computer based on 
renal function. The fraction of prescriptions deemed appropriate during the 
intervention vs control periods by dose was 67% vs 54% (P=.001) and by 
frequency was 59% vs 35% (P=.001). Guided medication dosing for inpatients 
with renal insufficiency appears to result in improved dose and frequency choices. 
This intervention demonstrates a way in which computer-based decision support 
systems can improve care. 
 Sturmer et al29 (2001) evaluated the interference of Nonsteroidal anti-
inflammatory drugs (NSAIDs) on renal function, but little is known about the 
effects of the half-life of these agents, or the use of other medications, on renal 
function. The result of the use of NSAIDs with a half-life of 4 or more hours (OR 
= 2.6; 95% CI: 1.2 to 5.7). Patients who used diuretics with NSAIDs (OR = 3.7; 
95% CI: 1.7 to 8.3) or without NSAIDs (OR = 3.5; 95% CI: 1.6 to 7.6) had a 
higher risk of impaired renal function than did patients using NSAIDs alone (OR 
= 1.6) or none of these drugs (reference). A similar but less pronounced pattern 
was observed for ACE inhibitors. NSAID-associated impaired renal function 
seems to be mainly the result of compounds with intermediate-long half-life. It 
was evidenced that the adverse effects of diuretics and ACE inhibitors on renal 
function were greater in those who also used NSAIDs. 
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SCOPE OF STUDY 
Kidney disease is a common, progressive illness that is becoming a global 
public health problem. Kidney disease rank third amongst life threatening disease 
after cancer and cardiac ailments. Older patients were at higher risk of developing 
a decline in renal function and the use of multiple medications to treat comorbid 
conditions. Indeed, the incidence of chronic kidney disease (CKD) is increasing 
alarmingly in most industrialized countries. For e.g. the prevalence of CKD 
among the Indian adult population was recently estimated to be > 13% (>25 
million adults), and the number of patients with ESRD alone has risen from 
209,000 in 1991 to 472,000 in 2004 whereas glomerulonephritis was one of the 
leading causes of kidney disease several decades ago.2  
Chronic kidney disease can affect glomerular blood flow and filtration, 
tubular secretion and reabsorption and renal bio activation and metabolism. Drug 
absorption, bioavailability, protein binding, distribution volume, and non-renal 
clearance (metabolism) also can be altered in this patients.5 
The adjustment of drug dosage to individual patient requirements can 
maximize therapeutic efficacy and minimize the adverse drug reactions. Dosages 
of drugs cleared renally are based on the renal function. The calculations are valid 
only when renal function is stable and serum creatinine level is constant. A dose 
adjustment in renal failure is especially critical because parent compounds or 
active metabolites can accumulate and cause additional morbidity and costs.  
CKD is a progressive condition marked by deteriorating kidney function. 
The GFR which is most frequently estimated by using the equation Cockroft- 
Gault that incorporates serum creatinine concentration along with demographic 
data is the most commonly used index of overall kidney function.  
The need for appropriate dose reduction in patients with renal failure is 
illustrated by earlier studies in which ranitidine-associated central nervous system 
(CNS) adverse drug reaction occurred more frequently in patients with renal 
impairment and the incidence of imipenem/cilastatin – associated seizures was 
reduced after dosage adjustment to renal function.8 Munepa et al.32 reported 
37.6% of potential dosing errors in the drugs prescribed for azotemic patients in 
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the medical wards of KholKaen hospital Thailand. Literature reveals that only few 
studies have assessed drug prescriptions and dosage adjustments in renal 
impairment.8 
Renal dysfunction affects more than just the renal clearance of drugs and 
/or active metabolites. A general guideline for administering drugs to patients with 
renal dysfunction is that when fe (fraction of the drug excreted unchanged in the 
urine) is >0.3, a dosage adjustment is most likely required at least in patients with 
severe renal impairment (ClCr<30mLmin−1. Also, patients with chronic renal 
failure have serious health problems and require multiple medications. Obviously, 
extra cautions warranted when prescribing drugs with narrow therapeutic index.2 
Many drugs which are prescribed to renal impaired patients like 
cephalosporins, aminoglycosides, fluroquinolones, beta-blockers, diuretics and 
hypoglycemic agents are eliminated primarily unchanged through the renal route.  
These drugs will create complications due to drug accumulation and should be 
adjusted to optimize the therapy.  Dose adjustment in renal impairment can easily 
be achieved by estimating creatinine clearance based on serum creatinine; and 
adjusting dose and/or dose interval. Dose adjustment in patients with renal failure 
reduce both the cost of the drug therapy and the risk of adverse drug reaction.8  
Literature reveals that only few studies have assessed drug prescriptions 
and dosage adjustments in renal impairment, hence the proposed study entitled 
“Dosage individualization of anti microbials and cardiovascular drugs in 
patients with chronic renal dysfunction” with the following objectives have 
been undertaken. 
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OBJECTIVES 
 
The aims of the present study are, 
 
 To understand the prescribing pattern of antimicrobials and cardiovascular 
drugs in patients with renal function impairment. 
 
 To understand drug dosage individualization of all renally excreted 
antimicrobials and cardiovascular drugs that necessitates dosage adjustment 
in patients with renal function impairment. 
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PLAN OF THE STUDY 
The proposed study entitled “Dosage individualization of anti 
microbials and cardiovascular drugs in patients with chronic renal 
dysfunction” was planned and carried out as given below, 
Phase 1 (December 2018) 
 Identification of research problem and scope of the study. 
 Preparation of study protocol. 
 Obtaining consent from the hospital authorities. 
 Literature survey 
Phase 2 (January 2018 to July 2018) 
 Design of structured proforma. 
 Patient selection, inclusion/exclusion criteria. 
 Data retrieval from general medicine department. 
 Estimating renal function status, evaluation of drug dosage appropriateness 
of all potentially nephrotoxic/ renally eliminated drugs. 
 Drug dosage adjustments. 
Phase 3 (August 2018) 
 Data analysis. 
 Report submission. 
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METHODOLOGY 
Study design: Prospective descriptive study. 
Study site: General medicine department of a 700 bedded multispecialty tertiary 
care teaching hospital. 
Study period: 9 months (December 2017– August 2018). 
Inclusion Criteria: Patients with estimated serum creatinine value more than 
1.7mg/dL (Normal range: 0.8 – 1.2 mg/dL), prescribed with at least one 
antimicrobial drug or cardiovascular drug or both are included in the study.37 
Exclusion Criteria: Patients with estimated serum creatinine value more than 
1.7mg/dL but with no antimicrobial drug or cardiovascular drug in the 
prescription are excluded from the study. Patients who are not willing to 
participate in study are excluded. 
Major outcome measure: The number or percentage of antimicrobial and 
cardiovascular drug dosage regimens adjusted to renal function. 
Methods: The study protocol was approved by institutional review board 
(Annexure-I). Patients with impaired renal function were identified based on 
laboratory data and clinical evaluation. Verbal consent was obtained from each 
subject before initiating the study. Structured proforma (Annexure-II) were used 
to collect various clinical and demographic details of the patient such as age, 
gender, body weight, length of hospital stay, primary diagnosis, serum urea and 
creatinine levels. Treatment data including prescribed drugs, dosages, frequency 
and route of administration were also recorded. 
For all prescribed drugs, the fraction of the bioavailable dose which is eliminated 
extra-renally (Q0) was obtained from literature. Dose adjustments was considered 
mandatory for those drugs with at least 70% of bioavailable, active form of drug is 
eliminated by the kidney in unchanged form (Q0≤ 0.3) as well as other potentially 
nephrotoxic drugs for which dose adjustment is recommended in the literature. 
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Creatinine clearance was calculated by using Cockroft-Gault equation.40 
𝐂𝐫𝐂𝐥 =
(140 − age) × Weight in kg
Sr. Cr × 72
 
 
Instead of creatinine clearance, GFR was calculated by using Modification of Diet 
in Renal Disease (MDRD) whenever patient’s weight was not available.37 
GFR = 186.3 × (Serum creatinine) -1.154 × (Age) -0.203 × 0.742(Female) 
 
For obese patients for whom actual body weight (ABW) was more than 
120% ideal body weight (IBW), the dosing weight was calculated40 before using 
Cockroft-Gault equation. 
𝐼𝐵𝑊 𝑓𝑜𝑟 𝑚𝑎𝑙𝑒 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 = [𝐻𝑒𝑖𝑔ℎ𝑡 (𝑐𝑚) − 80] × 0.7 
𝐼𝐵𝑊 𝑓𝑜𝑟 𝑓𝑒𝑚𝑎𝑙𝑒 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 = [𝐻𝑒𝑖𝑔ℎ𝑡 (𝑐𝑚) − 70] × 0.6 
𝐷𝑜𝑠𝑖𝑛𝑔 𝑊𝑒𝑖𝑔ℎ𝑡 = (𝐴𝐵𝑊 − 𝐼𝐵𝑊) × 0.4 + 𝐼𝐵𝑊 
         
Creatinine clearance, eGFR and IBW were calculated using Micromedex 
software.[REF] After determining the degree of renal insufficiency the patients was 
classified according to their stages of renal impairment as recommended by 
National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF 
KDOQI)43 and Food Drug  Administration (FDA).4 
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Stage Description eGFR(mL/min/1.73m2) CLcr(mL/min 
1 Control (normal) ≥ 90 ≥ 90 
2 Mild decrease in 
GFR 
60 – 89 60 - 89 
3 Moderate 
decrease in GFR 
30 – 59 30 – 59 
4 Severe decrease 
in GFR 
15 – 29 15 – 29 
5 End Stage Renal 
Disease (ESRD) 
<15 not on dialysis <15 not on 
dialysis 
Requiring dialysis Requiring dialysis 
 
After estimating creatinine clearance the dose of the medication of interest was 
then evaluated using the published drug dosing guidelines for the patient’s 
individual degree of renal impairment.40,45,46 Each medication was then 
categorized as either ‘dose adjusted’ if its dosing was found within the target 
range or ‘dose not adjusted’ if the prescribed dose exceeded the relevant dose 
threshold. 
When necessary, the new dosages or dosing intervals were accurately estimated 
by using the following formula: 44 
New Dose =
Patient ′s CrCl × Normal Dose
Normal CrCl
 
New Dosing Interval =
Normal CrCl × Normal Dose
Patient ′s CrCl
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RESULTS 
 
A total of 1016 drugs in 103 patients were evaluated in the present study 
with a mean of 10.13 ± 3.26 drugs per patient. The mean age of the study 
population was 58.42 ± 12.69(range 32 to 83yrs) with 70.87% male patients.  
Their mean Serum creatinine level was 5.48 mg% ± 3.04 (range 2.0 to 8.2 mg/dl) 
and mean creatinine clearance was 18.51mg/ml ± 10.05(range 8.47 to 34.8 
ml/min). Demographic details of these patients are shown in Table 1. Most of the 
patients (54.36%) were in the late adulthood (51-65yrs) and followed by 
adulthood (13.5%) which is shown in Table 2. The major diagnoses were renal 
failure (96.0%), hypertension (58.0%) and diabetes mellitus (34%). About 84% of 
patients had multiple co-morbidities. Table 3 shows the major diagnosis of all the 
patients. 
The stage distributions of renal impairment as per FDA are shown in 
Table 4; none of the patients selected had mild renal impairment; 13 had 
moderate, 17 had severe renal impairment and 20 had end stage renal dysfunction 
(ESRD). 
It was found that 17.59% of the prescribed drugs were renally eliminated 
with at least 70% of the drugs in unchanged form (ie. Q0<0.3)  or potentially 
nephrotoxic.  On an average each patient with a renal failure received about 2 
renally eliminated drug (Q<0.3) or nephrotoxic drugs. 
Vitamins and mineral supplements were most commonly prescribed 
(84%). The major drug category prescribed was antibiotics (13.04%), 
antihypertensives (11.07%) and antiulcer drugs (9.29%). The prescribing patterns 
of renally eliminated drugs are shown in Table 5 to 27. About 16% of patients 
were prescribed with 13 drugs and 12.24% with 12 drugs each.  Figure 1 
illustrated the number of drugs prescribed per patients. 
 Among the 1016 evaluated drugs, 98 (9.64%) required dose 
adjustments. Of these dose of 244 (24.01%) were adjusted at the time of 
prescribing and 83 (8.16%) were not adjusted. The prescribed drugs with dosages 
not adjusted and those with contraindications in renal impairment are detailed in 
Table 28. 
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  Major category of errors identified were overdose (61.53%), and wrong 
frequency of administration (23.07%). About 8% of the drugs were to be avoided 
strictly in renal impairment as per the available evidences. (Table 29) Further 95% 
of the patients needed dosage adjustment for at least one drug prescribed.  
It was found that 29.85% of prescribed drugs had drug-drug interactions. 
The most common interacting drugs were identified as torsemide vs. pantoprazole 
and ceftriaxone vs. torsemide. These were found in 4.17% and 2.78% of patients 
respectively. Interactions which can directly affect kidney function were also 
observed in 4 cases. (Table 30) 
Out of 1016 drugs prescribed 13.59% of drugs had narrow therapeutic 
index. These were prescribed in 18% of patients.  Theophylline (7.76%), digoxin 
(3.88%), prazosin (1.94%) and amikacin (4.85%) were the drugs with narrow 
therapeutic index (Table 31). 
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Table 1: Demographic Data 
S.No Parameters Value 
1.  N 103 
2.  Age 32-84years 
3.  Male, n (%) 73(70.87%) 
4.  Female (%) 30 (29.12%) 
5.  Body Weight 52-74kg 
6.  Serum creatinine 2.8-8.7mg/dL 
7.  Creatinine clearance 8.51mg/ml-35.6mg/ml 
 
 
Table 2: Age distribution (N=103) 
 
S.No Age (years) 
No. of 
patients 
Percentage 
(%) 
1.  Adolescents (13-18yrs) NIL NIL 
2.  Early adulthood (19-35yrs) 3 2.9% 
3.  Adulthood (36-50yrs) 14 13.5% 
4.  Late adulthood (51-65yrs) 56 54.3% 
5.  Young old (66-74yrs) 29 28.1% 
6.  Old (75-84yrs) 1 0.9% 
7.  Old old >85yrs NIL NIL 
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Table 3: Clinical conditions of patients (N=103) 
 
S. No. Clinical conditions 
No. of 
Patients 
Percentage 
(%) 
1.  Renal Failure 98 95.14% 
2.  Hypertension 84 81.55% 
3.  Diabetes Mellitus 85 82.52% 
4.  Pott’s spine 12 11.65% 
5.  COPD 8 7.76% 
6.  Gout 5 4.85% 
7.  CAD 6 5.82% 
8.  CVD 9 8.73% 
9.  CHF 42 40.77% 
10.  Asthma 12 11.65% 
11.  Anemia 2 1.94% 
12.  Hypothyroidism 2 1.94% 
13.  CVA 4 3.88% 
14.  IHD 1 0.97% 
 
 
 
Table 4: Stages of Renal impairment (N=103) 
 
 
 
Stages No. of Patients Percentage (%) 
Normal (>80ml/min) 0 0 
Mild (60 – 79ml/min) 0 0 
Moderate (30 – 49ml/min) 20 19.41% 
Severe (15 – 29ml/min) 46 44.66% 
ESRD (<15ml/min) 37 35.92% 
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Table 5: Prescribing pattern of renally eliminated drugs 
(N=1016) 
 
No. Category 
Total 
Drugs 
 
Percentage 
(%) 
No. of 
Patients 
Percentage 
(%) 
1.  
Vitamins & 
minerals 
87 8.56% 42 40.77% 
2.  Antibiotics 76 7.48% 40 38.83% 
3.  Antihypertensives 69 6.79% 42 40.77% 
4.  Antiulcer 57 5.61% 41 39.80% 
5.  Antiasthmatic 42 4.13% 28 27.18% 
6.  Analgesics 44 4.33% 22 21.35% 
7.  Antidiabetics 43 4.23% 27 26.21% 
8.  Diuretics      41 4.03% 23 22.33% 
9.  Antiemetics 38 3.74% 24 23.30% 
10.  
Hematopoietic 
Agents 
26 2.55% 15 14.56% 
11.  Sedatives 21 2.06% 13 7.76% 
12.  Anticoagulants 21 2.06% 19 10.67% 
13.  Uricosuric agents 19 1.87% 12 11.65% 
14.  Anti 
Hyperlipidemic 
9 0.88% 9 8.73% 
15.  Laxatives 8 0.78% 8 7.76% 
16.  Anticonvulsants 
+Antianxiety 
6 0.59% 6 5.82% 
17.  Cortisones 5 0.49% 5 4.85% 
18.  Antianginal 16 1.57% 7 6.79% 
19.  Hepatoprotective 4 0.39% 4 3.88% 
20.  Antiallergic 3 0.29% 3 2.91% 
21.  Antidiarrheal 1 % 1 0.97% 
22.  Cardiac glycosides 4 0.39% 4 3.88% 
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Table 6: Antihypertensives prescribed (N=196) 
 
S. No. Drugs Dosing Regimen No. of Patients 
Percentage 
(%) 
1.  Amlodipine 
2.5 mg OD/ 5mg 
OD 
37 18.87% 
2.  Nebivolol 2.5 mg OD/5mg OD 22 11.22% 
3.  Metoprolol 
25mg OD/ 50mg 
OD 
30 15.30% 
4.  Telmisartan 
20mg OD/ 40mg 
OD 
27 13.77% 
5.  Ramipril 2.5mg OD/5mg OD 4 2.04% 
6.  Carvedilol 
3.125mg OD/ 
12.5mg OD/25mg 
OD 
1 0.51% 
7.  Nifedipine 
2.5 mg OD/ 5mg 
OD 
18 9.18% 
8.  Metolazone 5mg OD 1 0.51% 
9.  Clonidine 100mcg OD 1 0.51% 
10.  Atenolol 
25mg OD/ 50mg 
OD 
1 0.51% 
11.  Prazosin 2.5mg OD 8 4.08% 
12.  Clinidipine 5mg OD, 10mg OD 32 16.32% 
13.  Slidenafil 20mg BD 14 7.14% 
S.No Drugs 
Dosing 
Regimen 
No. of 
Patients 
Percentage (%) 
1 Pantoprazole 40 mg OD 49 85.96% 
2 Sucralfate 
500mg/5ml 
BD 
2 3.50% 
3 Rabeprazole 20mg BD 2 3.50% 
4 Esomeprazole 20 mg BD 4 7.01% 
Table 7: Antiulcer drugs prescribed, (N=57) 
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                             Table 9: Diuretics prescribed (N=76) 
 
S. No. Drugs Dosing  Regimen 
No. of  
Patients 
Percentage 
(%) 
1.  Ceftriaxone 1g BD 30 21.73% 
2.  Meropenem 1gm BD 16 11.59% 
3.  Ornidazole 500mg OD 1 0.72% 
4.  Piperacillin + tazobactum 4.5g OD 29 21.01% 
5.  Ceftriaxone + Sulbactum 1.5g OD 16 11.59% 
6.  Ofloxacin 200mg OD 4 2.89% 
7.  Pyrazinamide 500mg BD 12 8.69% 
8.  Levofloxacin 500mg OD 5 3.62% 
9.  Amoxicillin + clavulnate 625mg OD 1 0.72% 
10.  Ciprofloxacin 500mg OD 5 3.62% 
11.  Amikacin 250mg OD 5 3.62% 
12.  Cefipime + Tazobactum 1.5mg OD 1 0.72% 
13.  Rifampicin +Isoniazid 400mg OD 13 9.42% 
S.No Drugs 
Dosing 
Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Furosemide 40mg OD 27 35.52% 
2.  Torsemide 10mg BD 23 30.26% 
3.  Spirinolactone 
25mg OD/ 
50 mgOD 
17 22.36% 
4.  Metalazone 2.5mg OD 7 9.21% 
5.  Hydrochlorthiazide 12.5mg OD 2 2.63% 
Table 8: Antibiotics prescribed (N=138) 
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Table 10: Antiasthmatic drugs prescribed (N=42) 
 
 
 
 
Table 11: Analgesics Prescribed (N=44) 
 
 
 
 
 
 
 
S.No Drugs 
Dosing 
Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Salbutamol / Albuterol 100mcg/puff 22 52.38% 
2.  Theophylline+ Etofylline 100mg BD 5 11.90% 
3.  Ipratropium Br 20mcg/puff 4 9.52% 
4.  Doxofylline 400mg OD 3 7.14% 
5.  Budesonide 200mcg/puff 4 9.52% 
6.  Monteleukast 10mg BD 2 4.76% 
7.  Bromhexine 4mg/ml 1 2.38% 
8.  Ambroxol 30mg/5ml 1 2.38% 
S.No Drugs 
Dosing 
Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Paracetamol 650mg TDS 26 59.09% 
2.  Tramadol 50mg/75mg BD 7 15.90% 
3.  Aspirin 75mg OD 6 13.63% 
4.  Diclofenac 
75mg/100mg 
BD 
5 11.36% 
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Table 12: Antidiabetic drugs prescribed (N=65) 
 
S.No Drugs Dosing Regimen 
No. of  
Patients 
Percentage 
(%) 
1.  Insulin 10-15 U 25 38.46% 
2.  Metformin 250mg/500mgOD 9 13.84% 
3.  Linagliptin 5mg OD 23 35.38% 
4.  Glipizide 2.5mg OD 7 10.76% 
5.  Pioglitazone 100mg OD 1 1.53% 
 
 
 
Table 13: Antiemetics Prescribed (N=67) 
 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Ramosetron 0.3mg TDS 6 8.95% 
2.  Ondansetron 4mg BD 49 73.13% 
3.  Domperidone 30mg BD 11 16.41% 
4.  Betahistine 10mg BD 1 1.49% 
 
 
 
 
Table 14: Laxatives prescribed (N=10) 
 
 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1. Lactulose 3.35g/5ml 6 60% 
2. Bisacodyl 5mg /ml 4 40% 
Results 
 
Dosage individualization of anti microbials and cardiovascular drugs in patients with chronic renal 
dysfunction                                                                                                                              P a g e  | 52 
Table 15: Sedatives prescribed (N=16) 
 
 
 
Table 16: Anticoagulants prescribed (N=68) 
 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentag
e (%) 
1.  Clopidogrel 75mg/150mg OD 28 41.17% 
2.  Enoxaparin 40mg 20 29.41% 
3.  Heparin 5000IU 20 29.41% 
 
 
Table 17: Anticonvulsants prescribed (N=6) 
 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1. Chlordiazepoxide 10mg BD 1 16.66% 
2. Pregabilin 150mg OD 5 83.33% 
 
                           Table 18: Corticosteroids Prescribed (N = 5) 
 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Hydrocortisone 100mg BD 2 40% 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Alprazolam 
0.25mg/0.5mg 
HS 
4 25% 
2.  Clonazepam 0.25mg/1mg HS 6 37.5% 
3.  Clobazam 5mg HS 5 31.25% 
4.  Lorazepam 1mg/2mg HS 1 6.25% 
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2.  Methyl prednisolone 10mg BD 2 40% 
3.  Deflazacort 1mg/ 6mg BD 1 20% 
 
 
 
Table 19: Antiallergic drugs prescribed (N=3) 
 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Hydroxazine 25mg OD 1 33.33% 
2.  Levocitrizine 5mg OD 2 66.66% 
 
 
 
Table 20: Hematopoetic agents prescribed (N=26) 
 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Folic acid 5mg BD 17 65.38% 
2.  Ferrous Ascorbate 600mg OD 6 23.07% 
3.  Ferrous Fumarate 600mg OD 3 11.53% 
 
 
Table 21: Urecosuric agents prescribed (N =33) 
 
S.No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Febuxostat 40mg BD 32 96.96% 
2.  Allopurinol 100mg BD 1 3.03% 
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Table 22: Antihyperlipidemics prescribed (N=58) 
 
S. No. Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Atorvastatin 10mg/20mg OD 36 62.06% 
2.  Rosuvastatin 5mg/10mg OD 13 22.41% 
 
 
Table 23: Hepatoprotective prescribed (N=43) 
 
S. No. Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1.  Silymarin 70mg/140mg BD 22 51.16% 
2.  Ursodeoxycholic acid 300mg OD 21 48.83% 
 
 
Table 24: Antianginals prescribed (N =40) 
 
S. No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1. Isosorbide mono nitrate 5mg/10mg OD 22 55% 
2. Trimetazidine 35mg BD 18 45% 
 
 
 
Table 25: Antidiarrhoeals prescribed (N= 3) 
 
 
 
 
 
 
 
 
 
S.No Drugs 
Dosing 
Regimen 
No. of 
Patients 
Percentage 
(%) 
1. Racecadotril 100mg OD 3 100% 
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Table 26: Vitamins & Minerals prescribed (N=135) 
 
 
 
S.No Drugs No. of Patients 
Percentage 
(%) 
1.  Multivitamin 57 42.22% 
2.  Mecobalamin 32 23.70% 
3.  Sodium Bicarbonate 11 8.14% 
4.  Alfacalcidol 2 1.48% 
5.  Calcium Carbonate 9 6.66% 
6.  Calcium Gluconate 1 0.74% 
7.  Calcium + D3 3 2.22% 
8.  Calcitriol 18 13.33% 
9.  Potassium chloride 1 0.74% 
10.  Calcium Acetate 1 0.74% 
 
 
 
Table 27: Cardioglycosides prescribed (N=4) 
 
S. No Drugs Dosing Regimen 
No. of 
Patients 
Percentage 
(%) 
1. Digoxin 0.25mg OD       4 100% 
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                                Table 28: Miscellaneous (N=121) 
 
 
S.No Drugs 
No. of 
Patients 
Percentage 
(%) 
1.  Alpha Ketoanalogue 27 22.31% 
2.  Preprobiotics 22 18.18% 
3.  Chloroquine 1 0.82% 
4.  Lactic acid 21 17.35% 
5.  Sevelamer carbonate 1 0.82% 
6.  Doxepin 1 0.82% 
7.  Dimethicone + Pancretin 1 0.82% 
8.  Thyroxine 2 1.65% 
9.  Clotrimazole 1 0.82% 
10.  N-acetyl Cystine + Taurine 3 2.47% 
11.  Buclizine 1 0.82% 
12.  Ursodeoxycholic acid 3 2.47% 
13.  Geroz o 15 12.39% 
14.  Tranexamic acid 1 0.82% 
15.  Lanthanum carbonate 1 0.82% 
16.  Calcitrol 33 27.27% 
17.  Serratiopeptidase 1 0.82% 
18.  Dextromatharpan 21 17.35% 
19.  Sodium dihydrogen citrate 1 0.82% 
20.  Albendazole 1 0.82% 
21.  EPOETIN 4000IU 12 9.91% 
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Table 30: Drug interactions of Antimicrobials and cardiovascular drugs, (N=66) 
Table 29: Types of errors identified (N=52) 
 
 
 
 
 
 
 
S. No Type of error No. of Patients Percentage (%) 
1. Overdose 32 61.53% 
2. Wrong frequency 12 23.07% 
3. Contraindicated 8 15.38% 
S.No Drugs Interaction 
% of 
Interactions 
Severity 
1 
Furosemide + 
Metoprolol 
Increase the risk of 
hyperkalemia 
1.39 Major 
2 
Metoprolol + 
Spironolactone 
Increase risk of 
hyperkalemia 
1.39 Major 
3 
Theophylline + 
Pantoprazole 
Increase the effects of 
theophylline 
1.39 Moderate 
4 
Theophylline + 
Tramadol 
Increased risk of seizures 1.39 Major 
5 
Ondansetron + 
Tramadol 
Decreased analgesic 
efficacy of tramadol 
1.39 Moderate 
6 
Hydrocortisone + 
Doxofylline 
Decrease the effect of 
theophylline 
1.39 Major 
7 
Ceftriaxone + 
Torsemide 
Increase risk of kidney 
failure 
2.79 Major 
8 
Propoxifen + 
Clobazam 
Increase CNS side effects 1.39 Major 
9 
Clopidogrel + 
Pantoprazole 
Decrease effect of 
clopidogrel 
1.39 Moderate 
10 
Clotrimazole 
+ Atorvastatin 
Increase the blood levels 
of atorvastatin 
1.39 Moderate 
11 
Metoprolol + 
Calcium 
carbonate 
Decrease the effects of 
metoprolol 
1.39 Major 
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12 
Metoprolol + 
Amlodipine 
Reduction heart 
rate,cardiac contractility 
1.39 Major 
13 
Doxepin + 
Propoxyphene 
Increase the effects other 
medication 
1.39 Major 
14 
Propoxyphene + 
Hydroxyzine 
Increase the effects such 
as dizziness, confusion, 
drowsiness 
1.39 Major 
15 
Ceftriaxone + 
Calcium gluconate 
Results in formation 
crystals in blood stream 
1.39 
Contraindi
-cated 
16 
Amlodipine + Calcium 
acetate 
Decreases the effect of 
amlodipine 
1.39 Moderate 
17 
Amlodipine + 
nebivolol 
Lowering the blood 
pressure 
1.39 Moderate 
18 
Alprazolam 
+Isosorbidemonotitrate 
Lowering blood pressure 1.39 Moderate 
19 Alprazolam + tramadol 
Increase the effects like 
dizziness,confusion 
1.39 Moderate 
20 Insulin + Torsemide 
Decrease efficacy of 
insulin 
1.39 Minor 
21 
Alprazolam + 
Spiranolactone 
Lowering the blood 
pressure 
1.39 Moderate 
22 
Calcium carbonate + 
Amlodipine 
Decreases the effects of 
amlodipine 
1.39 Moderate 
23 
Magnesium carbonate 
+ Ferrous ascorbate 
Decrease iron 
bioavailability 
1.39 Minor 
24 Insulin + Clonidine 
Results in hypo or 
hyperglycemia 
1.39 Minor 
25 
Theophylline + 
nebivolol 
Increase the effect of 
theophylline 
1.39 Major 
26 
Furosemide + 
Pantoprazole 
Results in 
hypomagnesemia 
2.78 Minor 
27 Ceftriaxone + calcium 
Precipitation in lungs & 
kidney 
1.39 Major 
28 Nebivolol +calcium 
Decreases the effects of 
nebivolol 
1.39 Major 
29 
Carvedilol + 
Torsemide 
Serum potassium level is 
altered 
1.39 Moderate 
30 
Calcium acetate + 
Carvedilol 
Decrease the effect of 
carvedilol 
1.39 Moderate 
31 Prazosin + Clinidipine 
Increase chance of 
hypotension 
1.39 Minor 
32 
Chloroquine + 
Ondansetron 
Increased risk of QT 
interval prolongation 
1.39 Major 
33 
Isoniazid + 
Rifamipicin 
Results in hepatotoxicity 1.39 Major 
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34 
Potassium chloride + 
Spiranolactone 
Results in hyperkalemia 1.39 Major 
35 
Clopidogrel + 
Torsemide 
Increased risk of 
torsemide toxicity 
1.39 Moderate 
36 
Moxifloxacin + 
Sucralfate 
Decreased moxifloxacin 
effectiveness 
1.39 Moderate 
37 
Levofloxacin + 
diclofenac 
Increased risk of seizure 1.39 Moderate 
38 
Tramadol + 
Levofloxacin 
Increased risk of seizures 1.39 Major 
39 Amikacin + diclofenac 
Increased chance of 
kidney damage 
1.39 Moderate 
40 
Amikacin + 
Pantoprazole 
Hypomagnesemia 1.39 Moderate 
41 
Ondansetron + 
Levofloxacin 
Increased risk of 
arrhythmia 
1.39 Moderate 
42 
Ciprofloxacin + 
Sodium bicarbonate 
Increased risk of stone 
formation 
1.39 Major 
43 
Ciprofloxacin + 
lactulose 
Increased risk of 
arrhythmi 
1.39 Minor 
45 
Ondansetron + 
Tramadol 
Decreased effect of 
Tramadol 
2.78 Minor 
46 
Amlodipine + 
Diclofenac 
Decreased effect of 
amlodipine 
1.39 Minor 
47 Atenolol + Diclofenac 
decreased effect of 
atenolol 
1.39 Major 
48 
Torsemide + 
Pantoprazole 
Hypomagnesemia 4.17 Minor 
49 
Aspirin + 
Hydrocortisone 
Aspirin effect gets 
reduced 
1.39 Major 
50 
Salbutamol + 
Toresemide 
Hypokalemia 1.39 Major 
51 
Ceftriaxone + 
Furosemide 
Increase chance of 
kidney damage 
2.78 Minor 
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Table 31: Antimicrobials and cardiovascular drugs with narrow 
therapeutic index (N=103) 
52 Albuterol + Carvedilol 
Inhibits activity of 
albuterol 
1.39 Major 
53 Levofloxacin + Insulin 
Increased effect of 
insulin 
1.39 Major 
54 
Prochlorperazine + 
Levofloxacin 
Increased QT interval 1.39 Major 
55 
Clopidogrel + 
Rabeprazole 
Inhibits activity of 
clopidogrel. 
1.39 Contraindicated 
56 
Metformin + 
Nebivolol 
Hypoglycemia 1.39 Minor 
57 
Calcium Gluconate + 
Ceftriaxone 
Fatal particulate 
precipitate in lungs 
and kidney 
1.39 Contraindicated 
58 
Furosemide + 
Ketorolac 
Decreased diuresis 1.39 Major 
59 
Spironolactone + 
Telmisartan 
Hyperkalemia 1.39 Moderate 
60 
Furosemide + 
Metoprolol 
Hypotention 1.39 Major 
61 
Atorvastatin + 
pantoprazole 
Increased risk of 
myopathy 
1.39 Minor 
62 
Furosemide + 
Nebivolol 
Hypotension 1.39 Major 
63 
Hydrocortisone + 
Nebivolol 
Hypotension 1.39 Minor 
64 
Alprazolam + 
Nebivolol 
Hypotension 1.39 Minor 
65 Aspirin + Amlodipine Hypertention 1.39 Minor 
66 
Hydrocortisone + 
amlodipine 
Hypertension 1.39 Minor 
S.No NTI Drugs No. of Patients Percentage (%) 
1.  Amikacin 5 4.85% 
2.  Theophylline 8 7.76% 
3.  Digoxin 4 3.88% 
4.  Prazosin 2 1.94% 
 Total 19 18.44% 
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DISCUSSION 
 Kidney plays vital physiological functions and it acts as the major 
excretory organ in the human body.  Renal function can be assessed by various 
tests and procedures that will help evaluate the kidney function.  Drug therapy in 
the presence of renal diseases requires to be individualized.  Some drugs are to be 
avoided and some others may require dose adjustments in order to avoid drug 
toxicity. 
 The major test which can be performed to assess the renal function is the 
estimation of serum creatinine in urine as well as blood. Creatinine is a by-product 
of muscle metabolism in the body and it is primarily eliminated through 
glomerular filtration. Thus the accumulation of creatinine in blood indicates 
abnormal or diminished renal function.47 
 The National Kidney Foundation-Kidney Disease Outcomes Quality 
Initiative (NKF KDOQI) advocates the use of creatinine clearance (CrCl) and 
estimated glomerular filtration rate (eGFR) for calculating the individualized dose.  
Once the CrCl or eGFR is estimated CKD is classified into five stages proposed 
by KDOQI and approved by FDA.  Estimation of GFR is done with the help of 
Modification of Diet in Renal Disease (MDRD) equation and CrCl by Cockroft-
Gault equation. (Roger K.)The Cockroft-Gault equation is still most often used for 
estimating GFR in pharmacokinetic studies and for drug dosage adjustments, 
although some studies have shown the MDRD equation to be more accurate for 
estimating GFR. 24 
 About 506 drugs were evaluated in terms of dosage appropriateness in 
patients with renal impairment and 21.14% required dose adjustments. Of these 
dose of 3.75% were adjusted at the time of prescribing and 17.39% were not 
adjusted.  The major categories of errors found in these unadjusted drugs were 
overdose, wrong frequency and inappropriate drug choice.  Falconnier ET al8 
reported 17% of inappropriate prescriptions which was almost comparable to the 
present study. A similar study 48 carried out in the nephrology department of the 
same study site showed only 7% inappropriateness. This may be due to the fact 
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that the drugs were prescribed by nephrologists whereas in the present study 
patients with renal impairment were managed in the general practice or general 
medicine department. Moreover, multiple co-morbidities of the study population 
and polypharmacy were the major reasons to expose them to various categories of 
drugs which can easily lead to dosing errors. 
 The study revealed that most of the dosage errors were seen with antibiotic 
containing prescriptions followed by antihypertensives. The major drug categories 
for which drug dosage adjustments were recommended based on the available 
evidence are discussed below. 
ANTIBIOTICS 
 A CRF case with UTI was prescribed with amoxicillin 1g twice daily. But 
literature (Micromedex) reveals that in severe renal impairment the maximum 
tolerated dose of amoxicillin is 1g per day. If accumulation of this drug occurs 
common side effects like epigastric distress, crystalluria, nephritis etc. would 
aggravate and result in complications like oral thrush, vaginal yeast infection etc. 
Hence for this patient a reduced dose of 500mg BD/ 1g OD of amoxicillin or an 
alternate therapy with dose adjusted ciprofloxacin was recommended.  
Garamycin was prescribed for a patient with venous ulcer at a dose of 80 mg q12h 
which will lead to accumulation of drug and can even cause resistance. As per the 
literature 40 the adjusted dose of garamycin in patients having moderate renal 
failure should be the normal dose given at every 36 hrs. 
 Also, another antibiotic called cefepime was prescribed for prophylaxis of 
secondary infection with a dose of 1 g given two times daily. In this condition the 
half-life of cepfepime will tend to increase fivefold and will lead to accumulation 
of drug. This results in increased chance of severe ADR like toxic epidermal 
necrolysis, encephalopathy and seizures. Hence, 500 mg BD or 1 g OD was 
recommended. 
 Another cephalosporin which required dose individualization was 
cefperazone whose usual dose is 2g twice daily but in decreased renal function its 
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level in plasma tend to increase and cause severe ADR like Steven-Johnson 
syndrome, epidermal necrolysis etc. Hence the dose should be adjusted to 1 gm 
per day to minimize such complications. Cefexime which does not require any 
adjustment can be a safe and suitable alternative. 
 Fluroquinolones such as levofloxacin, and ciprofloxacin were prescribed 
for various infections at a dose of 500 mg once daily. The treatment continued for 
several days during the hospital stay. In situation of impaired renal function the 
serum concentration of drug will increase rapidly and tend to cause toxicity. It 
worsens the renal function as well as it affects the liver. Thus it became 
mandatory to adjust the dose to 1 g repeated three times per week for levofloxacin 
and 400mg once daily (max) for ciprofloxacin so that the drug concentration will 
remain in therapeutic range.  
 Ofloxacin, which is another fluroquinolone requires dose individualization 
as it causes increased risk of tendonitis and tendon rupture if administered in 
normal adult doses for patients having renal failure. Thus it is recommended to 
give half the usual dose to minimize toxicity. 
 Amikacin, an aminoglycoside antibiotic was administered for symptoms of 
mycobacterial infection with a dose of 500 mg twice daily for a patient who was 
in end stage renal diseases (ESRD).In such a condition, the dose of amikacin 
should be adjusted to avoid complications like nephrotoxicity and ototoxicity. The 
modified dose in this case was 500mg repeated three times a week.  
ANTIHYPERTENSIVES 
 The current study documented few CRF patients receiving nebivolol, a 
cardioselective beta-blocker, at a dose of 5 mg OD and angiotensin converting 
enzyme inhibitor, rampril 5mg BD. Nebivolol is a nephrotoxic drug which causes 
reduced renal blood flow and reduced renal function which will further enhance 
the deleterious effect on renal function. The proposed dose of nebivolol in CRF 
cases is 2.5 mg once daily so that nephrotoxic effects are minimized. 25 
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 ACE inhibitors like ramipril is also considered nephrotoxic drug and in 
most SHT cases it was administered as 5mg twice daily dosage. But international 
indices 40 suggests that maximum tolerated dose of ramipril in RF patients is 2.5 
mg up to a maximum of 5mg per day. 
DIURETICS 
 Few cases with comorbidities like SHT, CHF and CRF were treated with 
potassium sparing diuretics like spironolactone and eplerenone for edema as well 
to reduce systemic blood pressure. But for a CRF patient these drugs are 
recommended to be avoided from pharmacotherapy. 
 A case of past medical history having SHT was continued on 
hydrochlorthiazide 12.5 mg once daily which should be avoided in renal 
impairment as the cumulative effect of thiazide in body will precipitate azotemia 
which will further impair the renal function.40 
ANTIDIABETICS 
 Metformin is a drug frequently prescribed in T2DM at a dose of 500mg 
once daily.  In renal impairment the elimination of metformin and its metabolites 
diminishes, leading to drug accumulation. This precipitates fatal condition like 
lactic acidosis and hence the use of metformin in renal failure patients is 
contraindicated.  
 Another antidiabetic drug of interest is glipizide which is usually 
prescribed at a dose of 2.5 mg twice daily. At this dose accumulation is common 
in renal impaired patients and will end up in hypoglycemic coma which is very 
severe.  Hence it is not recommended to be continued in therapy for RF patients. 
ANALGESICS 
 Tapendalol 50mg thrice daily was prescribed in a case having CrCl< 
30ml/min. The Area Under the Curve (AUC) of tapendalol is higher and lead to 
nephrotoxicity in such cases. So tapendalol use should be avoided in renal failure. 
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 In renal impairment the elimination of paracetamol is profoundly 
diminished which will lead to accumulation of NAPQI, a toxic metabolite of 
paracetamol in renal tissues and it may lead to complete organ damage. So it is 
advised to increase the dosing interval of paracetamol to minimize the toxic 
effects. 
ANTIHYPERLIPIDEMICS 
 Rosuvastatin 10mg daily was prescribed in a case with hyperlipidemia and 
severe renal impairment.  Overdosage of rosuvastatin due to reduced elimination 
can cause breakdown of skeletal muscle tissues (rhabdomylosis) and can 
aggravate the renal failure conditions. As per the literature, 5mg daily of 
rosuvastatin is recommended in renal impairment or it can be alternated with 
atorvastatin 10mg/20mg OD which is found to be rather safe in renal failure. 
OTHER DRUGS 
 In one case of CRF potassium chloride was prescribed which may cause 
hyperkalemia and related cardiac complications like tachyarrhythmia. So the use 
of KCl should be avoided in such conditions. An important anticoagulant 
enoxaparin will have increased exposure in the body as the elimination of drug is 
drastically reduced in renal failure. This can cause fatal haemorrhagic 
complications and hence the dose should be titrated to optimize the blood thinning 
and reduce problems. 40 
Conclusion 
 
Dosage individualization of anti microbilas and cardiovascular drugs in patients with chronic 
renal dysfunction                                                                                                                  
                                                                                                              P a g e  | 70 
CONCLUSION 
 
The present study was carried out in order to understand the prescribing 
pattern of drugs in patients with renal impairment and to evaluate them in terms of 
dosage appropriateness. Modification of Diet in Renal Disease and Cockroft-Gault 
formula was used to calculate patient’s eGFR or creatinine clearance and dosage 
appropriateness was then assessed using published drug dosing guidelines and 
relevant equations. 1016 drugs in 103 patients were evaluated in the present study 
with an average of 10 drugs per patient. Of these 1016 studied drugs, 98 (9.64%) 
required dose adjustment where 244 (24.01%) were adjusted and 83 (8.16%) were 
not adjusted. It was found also that most of the drugs requiring dose adjustment 
were antibiotics (41.77%) followed by antihypertensives (13.67%). Major types of 
errors identified were overdosage and wrong frequency of administration. About 
15.38% of drugs were to be avoided. However the current study observed that the 
prescribed drug dosage follows the recommended guidelines to a greater extent 
and are comparable with the existing literature. Continued collaboration with 
clinical pharmacist should be encouraged for improving therapeutic outcome in 
patients with renal impairment. 
Future outlook 
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FUTURE OUTLOOK 
 
 
Further studies are needed in order to assess the impact of 
pharmacist intervention on improving drug dosage adjustment in 
patients with renal impairment. The present study may be extended to 
the other department of the hospital.  
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